Reglagene, Inc. Announces closing of $5.4 Million Private Placement

Company developing breakthrough therapies for brain diseases has closed oversubscribed private placement to fund clinical trial planning and R & D.

Inability to penetrate the blood-brain barrier has been a roadblock to treat brain diseases. Reglagene has addressed this and paves the way in therapies offering brain cancer patients new hope.” — Richard Austin, Ph.D., MBAContinue reading

Xcellerant Ventures Invests in Series A Funding Round for Lenoss Medical

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone.Continue reading

C-Path Welcomes Mucopolysaccharidosis Clinical Trial Data Contribution from Children’s Hospital of Orange County into RDCA-DAP

TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Children’s Hospital of Orange County (CHOC) has generously contributed clinical trial data related to mucopolysaccharidosis (MPS), reinforcing the power of collaboration in advancing rare disease research.Continue reading

Avery Therapeutics, Inc. shares publication in Nature Communications Biology: “Biologically derived epicardial patch induces macropha​ge mediated pathophysiologic repair in chronically infarcted swine hearts”

TUCSON, ARIZONA, DECEMBER 11, 2023 – Avery Therapeutics, Inc., a privately held, pre-clinical stage therapeutics company, developing therapeutics for diseases of aging, inflammation and fibrosis announces a publication in Nature Communications Biology, dated November 24, 2023. The article, titled “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts,” demonstrates a novel approach in the treatment of chronic heart failure (CHF).Continue reading